Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database

Basit Öğe Kaydı
dc.authoridUcar, Gokhan/0000-0002-7649-1075
dc.authoridCan, Orçun/0000-0002-9400-105X
dc.authoridErturk, Ismail/0000-0001-6835-0988
dc.authoridÖksüzoğlu Çakmak, Ömür Berna/0000-0002-2756-8646
dc.authoridYekedüz, Emre/0000-0001-6819-5930
dc.authoridHizal, Mutlu/0000-0001-5147-4431
dc.authoridKucukarda, Ahmet/0000-0001-7399-2360
dc.authorwosidUcar, Gokhan/AAA-8198-2021
dc.authorwosidKarakaya, Serdar/ABF-6887-2021
dc.authorwosidHizal, Mutlu/AHD-7752-2022
dc.authorwosidCan, Orçun/AGX-9627-2022
dc.authorwosidErturk, Ismail/B-4317-2019
dc.authorwosidKüçükarda, Ahmet/AGF-2120-2022
dc.authorwosidÖksüzoğlu Çakmak, Ömür Berna/HKN-6428-2023
dc.contributor.authorYekeduz, Emre
dc.contributor.authorErturk, Ismail
dc.contributor.authorTural, Deniz
dc.contributor.authorKaradurmus, Nuri
dc.contributor.authorKarakaya, Serdar
dc.contributor.authorHizal, Mutlu
dc.contributor.authorArikan, Rukiye
dc.date.accessioned2024-06-12T11:07:08Z
dc.date.available2024-06-12T11:07:08Z
dc.date.issued2021
dc.departmentTrakya Üniversitesien_US
dc.description.abstractLay abstract Nivolumab is an immune checkpoint inhibitor (ICI) that blocks the communication between T cells and cancer cells and instead activates T cells to fight against cancer. Metastatic renal cell carcinoma (mRCC) is one of the most susceptible tumors to ICIs. The Checkmate 025 trial showed the efficacy of nivolumab in patients with previously treated mRCC. In this real-world study, 173 patients with mRCC were treated with nivolumab in the second line and beyond. Nivolumab was effective in the real-world setting without additional safety concerns. Aim: The authors present real-world data on the efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma (mRCC). Methods: The Turkish Oncology Group Kidney Cancer Consortium (TKCC) database includes patients with mRCC from 13 cancer centers in Turkey. Patients with mRCC treated with nivolumab in the second line and beyond were extracted from the TKCC database. Results: A total of 173 patients were included. The rates of patients treated with nivolumab in the second, third, fourth and fifth lines were 47.4%, 32.4%, 14.5% and 5.7%, respectively. The median overall survival and progression-free survival were 24.2 months and 9.6 months, respectively. Nivolumab was discontinued owing to adverse events in 11 (6.4%) patients. Conclusion: Nivolumab was effective in patients with mRCC and no new safety signal was observed.en_US
dc.identifier.doi10.2217/fon-2021-0717
dc.identifier.endpage4869en_US
dc.identifier.issn1479-6694
dc.identifier.issn1744-8301
dc.identifier.issue35en_US
dc.identifier.pmid34726480en_US
dc.identifier.scopus2-s2.0-85120620215en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage4861en_US
dc.identifier.urihttps://doi.org/10.2217/fon-2021-0717
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21921
dc.identifier.volume17en_US
dc.identifier.wosWOS:000713725100001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherFuture Medicine Ltden_US
dc.relation.ispartofFuture Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectImmunotherapyen_US
dc.subjectKidney Canceren_US
dc.subjectNivolumaben_US
dc.subjectRenal Cell Carcinomaen_US
dc.subjectManagementen_US
dc.subjectEverolimusen_US
dc.subjectSunitiniben_US
dc.subjectOutcomesen_US
dc.subjectTherapyen_US
dc.subjectBrainen_US
dc.titleNivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium databaseen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu